GO:0004032 aldose reductase [NAD(P)H] activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004032 describes the molecular function aldose reductase [NAD(P)H] activity, which catalyzes the reversible NAD(P)H-dependent reduction of aldoses to alditols (polyols).
• The reaction is central to the polyol pathway, where glucose is reduced to sorbitol and then oxidized to fructose, a metabolic route implicated in diabetic complications and cancer growth [3,5].
• Enzymes with this activity belong to the aldo-keto reductase superfamily and accept a broad range of substrates, including aldoses, isocorticosteroids, and xenobiotic carbonyls.
• Aldose reductase [NAD(P)H] activity is not limited to mammals; it is found in xylose-assimilating yeasts such as Candida tenuis and in bacteria such as Pseudomonas aeruginosa [2,4].
• Dysregulated aldose reductase activity contributes to basement membrane thickening in diabetes and supports non-small cell lung cancer survival via fructose production [3,5].
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of aldose reductase function in health and disease.
Description
Aldose reductase [NAD(P)H] activity (GO:0004032) is a molecular function defined by the catalysis of the reaction: an alditol + NAD(P)+ = an aldose + NAD(P)H + H+. This oxidoreductase activity is responsible for the NAD(P)H-dependent conversion of aldoses to their corresponding polyols, a reaction that sits at the heart of the polyol pathway. The enzyme responsible, aldose reductase, is a member of the aldo-keto reductase superfamily and is widely expressed across species, from mammals to yeasts and bacteria [2,4]. Researchers study GO:0004032 because it links glucose metabolism to osmotic stress, redox balance, and biosynthetic precursor supply. In diabetic tissues, increased flux through this activity leads to sorbitol accumulation and basement membrane thickening, a hallmark of diabetic microvascular complications. More recently, polyol pathway-generated fructose has been shown to be indispensable for the growth and survival of non-small cell lung cancer cells, highlighting a renewed interest in this activity as a metabolic vulnerability. Beyond glucose, enzymes with aldose reductase [NAD(P)H] activity can reduce isocorticosteroids and a variety of carbonyl compounds, suggesting broader roles in detoxification and hormone metabolism. The availability of structural and biochemical data from yeast and bacterial homologs further supports mechanistic and evolutionary studies of this activity [2,4]. Understanding GO:0004032 therefore requires integrating enzymology, structural biology, and disease models.
aldose reductase [NAD(P)H] activity At A Glance
| GO ID | GO:0004032 |
|---|---|
| GO term | aldose reductase [NAD(P)H] activity |
| Ontology | molecular_function |
| Synonym | aldehyde reductase activity; alditol:NAD(P)+ 1-oxidoreductase activity; alditol:NADP+ 1-oxidoreductase activity; aldose reductase activity; aldose reductase (NADPH) activity; polyol dehydrogenase (NADP(+)) activity |
| Definition | Catalysis of the reaction: an alditol + NAD(P)+ = an aldose + NAD(P)H + H+. |
| Major function | NAD(P)H-dependent reduction of aldoses to alditols (polyols), a key step in the polyol pathway. |
| Cofactor | NAD(P)H as electron donor; NAD(P)+ as electron acceptor. |
| Substrate range | Aldoses, isocorticosteroids, and various carbonyl compounds. |
| Representative enzymes | Aldose reductase (AKR1B1), aldehyde reductase, and homologous enzymes in yeast and bacteria [2,4]. |
What Is GO:0004032?
GO:0004032, aldose reductase [NAD(P)H] activity, is a molecular function that catalyzes the reversible oxidoreduction between an alditol and an aldose using NAD(P)+ as an electron acceptor and producing NAD(P)H and a proton. In the forward direction, an aldose is reduced to its corresponding polyol (alditol) at the expense of NAD(P)H. The term encompasses synonyms such as aldehyde reductase activity, alditol:NAD(P)+ 1-oxidoreductase activity, and polyol dehydrogenase (NADP(+)) activity, reflecting the broad substrate tolerance and cofactor usage of enzymes in this class [2,8].
Why Is aldose reductase [NAD(P)H] activity Important in Cell Biology?
GO:0004032 is important because it governs the first and rate-limiting step of the polyol pathway, a metabolic route that converts glucose to fructose via sorbitol. This activity influences osmotic balance, NADPH consumption, and the generation of fructose, which can feed glycolysis and biosynthetic pathways. In diabetes, increased aldose reductase activity is linked to sorbitol accumulation and basement membrane thickening, contributing to retinopathy, nephropathy, and neuropathy. In cancer, polyol pathway-generated fructose supports non-small cell lung cancer growth and survival, making this activity a potential therapeutic target. Additionally, the broad substrate specificity of enzymes with this activity implicates them in detoxification of reactive carbonyls and in steroid metabolism.
• Catalyzes the first step of the polyol pathway, converting glucose to sorbitol.
• Links glucose metabolism to fructose production, which supports cancer cell growth.
• Contributes to diabetic complications such as basement membrane thickening.
• Consumes NADPH, thereby affecting cellular redox balance.
• Exhibits broad substrate specificity, including isocorticosteroids and xenobiotic carbonyls.
• Is conserved across species, from yeast to humans, enabling comparative studies [2,4].
• Represents a potential drug target for diabetic complications and cancer [3,5].
• Provides a model system for studying aldo-keto reductase structure-function relationships [4,7].
Molecular Mechanism of aldose reductase [NAD(P)H] activity
Substrate binding and cofactor preference
In simple terms: The enzyme grabs a sugar molecule and a helper molecule called NADPH to start the reaction.
Enzymes with aldose reductase [NAD(P)H] activity bind an aldose substrate and a nicotinamide cofactor (NADH or NADPH) in a ordered or random sequential mechanism. The Candida tenuis enzyme exhibits a preference for NADPH over NADH, with kinetic constants reflecting this selectivity. Structural studies of a Pseudomonas aeruginosa carbonyl reductase show a conserved Rossmann-fold domain for cofactor binding and a substrate-binding pocket that accommodates various carbonyl compounds. The enzyme from thyroidectomized chicken fatty liver also displays NAD(P)H-dependent activity with a distinct substrate profile.
Catalytic reduction of aldose to alditol
In simple terms: The enzyme transfers a hydrogen from NADPH to the sugar, turning it into a sugar alcohol.
The catalytic mechanism involves hydride transfer from the C4 position of the nicotinamide ring to the carbonyl carbon of the aldose, followed by protonation of the resulting oxyanion by a conserved tyrosine residue. This reduces the aldose to its corresponding alditol (polyol). For example, glucose is reduced to sorbitol, the first step of the polyol pathway. The reaction is reversible, and the enzyme can also oxidize alditols back to aldoses using NAD(P)+ as an electron acceptor.
Broad substrate specificity and isocorticosteroid reduction
In simple terms: The enzyme is not picky; it can work on many different molecules besides sugars.
Aldose and aldehyde reductases exhibit isocorticosteroid reductase activity, reducing isocorticosteroids such as 17-hydroxy-20-oxosteroids. This broad specificity suggests roles beyond glucose metabolism, including steroid hormone regulation and detoxification of reactive carbonyls. The Pseudomonas aeruginosa enzyme also reduces a range of carbonyl substrates, underscoring the functional diversity within this activity class.
Structural determinants of activity
In simple terms: The shape of the enzyme determines which molecules it can grab and how fast it works.
Crystal structures of NAD(P)H-dependent carbonyl reductases reveal a conserved TIM-barrel fold with a catalytic tetrad of Tyr, Lys, His, and Asp residues [4,7]. The substrate-binding pocket varies among homologs, explaining differences in substrate specificity and inhibitor sensitivity. The Candida tenuis aldose reductase structure provides insights into cofactor binding and the molecular basis for NADPH preference.
Regulation by cellular redox and metabolic state
In simple terms: The enzyme's speed depends on how much NADPH and substrate are available in the cell.
Because the reaction consumes NADPH, aldose reductase activity is sensitive to the cellular NADPH/NADP+ ratio. Under hyperglycemic conditions, increased glucose flux drives the reaction forward, leading to sorbitol accumulation [3,5]. The enzyme can also be regulated by oxidative stress, which affects cofactor availability and enzyme modification. In cancer cells, polyol pathway flux is enhanced to meet fructose demand, indicating metabolic regulation of this activity.
Key Genes Involved in GO:0004032 aldose reductase [NAD(P)H] activity
The following genes encode enzymes or related proteins that exhibit or regulate aldose reductase [NAD(P)H] activity, based on published biochemical and structural studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AKR1B1 | Primary aldose reductase in humans; reduces glucose to sorbitol | Target for diabetic complications and cancer metabolism [3,5] |
| AKR1B10 | Aldo-keto reductase with retinal and carbonyl reductase activity | Implicated in cancer and detoxification; structural homolog of AKR1B1 |
| AKR1A1 | Aldehyde reductase; reduces a broad range of aldehydes | Overlaps with aldose reductase activity; isocorticosteroid reduction |
| Candida tenuis AR | NAD(P)H-dependent aldose reductase in xylose-assimilating yeast | Model for cofactor specificity and kinetics |
| Pseudomonas aeruginosa crc | NAD(P)H-dependent carbonyl reductase | Structural model for substrate binding |
| Chicken carbonyl reductase | Novel NAD(P)H-dependent carbonyl reductase in fatty liver | Catalytic properties and crystal structure |
| NQO1 | NAD(P)H:quinone oxidoreductase | Polymorphic activity; not aldose reductase but related NAD(P)H-dependent oxidoreductase |
| SORD | Sorbitol dehydrogenase; oxidizes sorbitol to fructose | Second step of polyol pathway; complements aldose reductase |
| TXN | Thioredoxin; regulates redox state | Indirectly affects NADPH availability for aldose reductase |
| G6PD | Glucose-6-phosphate dehydrogenase; generates NADPH | Supplies NADPH for aldose reductase activity |
| IDH1 | Isocitrate dehydrogenase 1; produces NADPH | Contributes to NADPH pool for reductive biosynthesis |
| ME1 | Malic enzyme 1; generates NADPH | Supports NADPH-dependent reactions including aldose reductase |
| CBR1 | Carbonyl reductase 1; NADPH-dependent reduction of carbonyls | Functional overlap with aldose reductase |
| AKR7A2 | Aflatoxin aldehyde reductase | Related aldo-keto reductase with detoxification roles |
| AKR1C1 | 20-alpha-hydroxysteroid dehydrogenase | Isocorticosteroid reductase activity similar to aldose reductase |
| AKR1C2 | Type 3 3-alpha-hydroxysteroid dehydrogenase | Broad substrate specificity including steroids |
| AKR1D1 | Delta-4-3-ketosteroid-5-beta-reductase | Steroid metabolism; related to isocorticosteroid reduction |
| HSD11B1 | 11-beta-hydroxysteroid dehydrogenase type 1 | Reduces cortisone to cortisol; NADPH-dependent |
How Is aldose reductase [NAD(P)H] activity Regulated?
Aldose reductase [NAD(P)H] activity is regulated at multiple levels. Transcriptionally, the AKR1B1 gene is induced by hyperglycemia and osmotic stress via tonicity-responsive enhancer binding protein (TonEBP). Post-translationally, the enzyme can be modified by phosphorylation and S-nitrosylation, affecting its catalytic efficiency. Metabolically, the activity is governed by the availability of NADPH, which is supplied by the pentose phosphate pathway (G6PD), malic enzyme (ME1), and isocitrate dehydrogenase (IDH1). In cancer cells, oncogenic signaling can upregulate polyol pathway flux to support fructose production. Additionally, competitive inhibitors such as sorbinil and tolrestat have been used to modulate activity in preclinical models.
aldose reductase [NAD(P)H] activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AKR1B1 | Diabetic retinopathy, nephropathy, neuropathy | Knockout mouse or patient-derived organoids |
| AKR1B1 | Non-small cell lung cancer growth | Xenograft or orthotopic NSCLC models |
| AKR1A1 | Isocorticosteroid reduction; endocrine imbalance | Cell-based assays with steroid substrates |
| SORD | Sorbitol dehydrogenase deficiency; polyol pathway flux | Knockout cell lines and metabolic flux analysis |
| G6PD | NADPH supply for aldose reductase; cancer metabolism | Overexpression and knockout models |
Diabetic complications
Increased aldose reductase [NAD(P)H] activity under hyperglycemic conditions leads to sorbitol accumulation in tissues such as the retina, kidney, and peripheral nerves. This osmotic stress and subsequent metabolic imbalances contribute to basement membrane thickening, a hallmark of diabetic microangiopathy. Inhibitors of this activity have been investigated to prevent or delay diabetic retinopathy, nephropathy, and neuropathy.
Non-small cell lung cancer
Polyol pathway-generated fructose is indispensable for the growth and survival of non-small cell lung cancer (NSCLC) cells. Aldose reductase [NAD(P)H] activity drives the first step of this pathway, and its inhibition reduces fructose production and impairs tumor growth in preclinical models. This positions the activity as a metabolic vulnerability in NSCLC.
Steroid metabolism and endocrine disorders
Aldose and aldehyde reductases exhibit isocorticosteroid reductase activity, converting isocorticosteroids to their reduced forms. This links GO:0004032 to steroid hormone metabolism and potentially to endocrine disorders, although the physiological relevance requires further investigation.
From aldose reductase [NAD(P)H] activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of aldose reductase activity impair tumor growth? | AKR1B1 knockout cancer cell lines and xenografts |
| How does a point mutation affect catalytic efficiency? | CRISPR point-mutation knock-in of catalytic residues [2,4] |
| Can a tagged version reveal subcellular localization? | Knock-in of fluorescent or epitope tag at endogenous locus |
| Does overexpression mimic diabetic conditions? | Tet-inducible overexpression of AKR1B1 in retinal or kidney cells |
| What is the role of NADPH supply in activity? | Knockout of G6PD or ME1 in combination with AKR1B1 |
| Is isocorticosteroid reduction physiologically relevant? | Overexpression of AKR1A1 or AKR1B1 in steroidogenic cells |
How to Study the aldose reductase [NAD(P)H] activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NAD(P)H oxidation assay | Enzymatic activity | Kinetic characterization and inhibitor testing |
| X-ray crystallography | Three-dimensional structure | Substrate and cofactor binding studies [4,7] |
| 13C metabolic flux analysis | Flux through polyol pathway | Cancer and diabetes metabolism |
| CRISPR knockout screening | Gene essentiality and drug sensitivity | Identifying modifiers of aldose reductase activity |
| RNA-seq | Transcriptional changes | Expression profiling of AKR1B1 and related genes |
| Proteomics | Protein abundance and modifications | Post-translational regulation of aldose reductase |
| Site-directed mutagenesis | Role of specific residues | Catalytic mechanism elucidation [2,4] |
| Inhibitor profiling | IC50 and selectivity | Drug discovery for diabetic complications |
Enzymatic activity assays
Spectrophotometric assays monitoring NAD(P)H oxidation at 340 nm are standard for measuring aldose reductase [NAD(P)H] activity. These assays use aldose substrates such as glucose or glyceraldehyde and can be adapted for high-throughput inhibitor screening [2,4].
Structural biology
X-ray crystallography and cryo-EM provide atomic-level insights into substrate binding and catalysis. Structures of Candida tenuis aldose reductase and Pseudomonas aeruginosa carbonyl reductase have revealed key residues for cofactor and substrate recognition [2,4,7].
Metabolic flux analysis
Isotope tracing with 13C-labeled glucose can quantify flux through the polyol pathway, measuring sorbitol and fructose production. This method is valuable for assessing the contribution of aldose reductase activity to cancer metabolism.
CRISPR screening and transcriptomics
Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to aldose reductase inhibitors. RNA-seq and proteomics complement these screens by revealing expression changes in polyol pathway genes under different conditions [3,5].
How CRISPR Can Be Used to Study GO:0004032 aldose reductase [NAD(P)H] activity
Knockout
CRISPR-Cas9 knockout of AKR1B1 or its homologs eliminates aldose reductase [NAD(P)H] activity, enabling studies of polyol pathway dependence in cancer and diabetes models. Knockout cell lines can be used to validate inhibitor specificity and to assess metabolic rewiring.
Point Mutation
Point mutations in catalytic residues (e.g., Tyr48, Lys77, His110, Asp43) can be introduced via CRISPR base editing or homology-directed repair to dissect the catalytic mechanism and cofactor preference. Such models help distinguish between NADH and NADPH utilization [2,4].
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins at the endogenous AKR1B1 locus allows real-time tracking of protein localization and interaction without overexpression artifacts. This approach is useful for studying subcellular distribution under hyperglycemic conditions.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of AKR1B1 can model the increased aldose reductase activity seen in diabetic tissues and cancers. Overexpression models are valuable for testing whether elevated activity is sufficient to drive pathological phenotypes [3,5].
How EDITGENE Supports aldose reductase [NAD(P)H] activity Research
Researchers studying aldose reductase [NAD(P)H] activity-related genes often need to determine whether a candidate gene is causally involved in metabolic, oncogenic, or diabetic phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for aldose reductase [NAD(P)H] activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| AKR1C3 Knockout HEK293 Cell Line | EDJ-KQ1964 | Human | 8644 | Details Get a Quote |
| ADH4 Knockout HEK293 Cell Line | EDJ-KQ2163 | Human | 127 | Details Get a Quote |
| AKR1C1 Knockout HEK293 Cell Line | EDJ-KQ2471 | Human | 1645 | Details Get a Quote |
| AKR1A1 Knockout HEK293 Cell Line | EDJ-KQ2641 | Human | 10327 | Details Get a Quote |
| AKR1B1 Knockout HEK293 Cell Line | EDJ-KQ4040 | Human | 231 | Details Get a Quote |
| AKR1C4 Knockout HEK293 Cell Line | EDJ-KQ4264 | Human | 1109 | Details Get a Quote |
| AKR1C2 Knockout HEK293 Cell Line | EDJ-KQ4431 | Human | 1646 | Details Get a Quote |
| AKR7A2 Knockout HEK293 Cell Line | EDJ-KQ5600 | Human | 8574 | Details Get a Quote |
| AKR1D1 Knockout HEK293 Cell Line | EDJ-KQ5840 | Human | 6718 | Details Get a Quote |
| AKR1E2 Knockout HEK293 Cell Line | EDJ-KQ9863 | Human | 83592 | Details Get a Quote |
| AKR1B10 Knockout HEK293 Cell Line | EDJ-KQ12322 | Human | 57016 | Details Get a Quote |
| AKR1B15 Knockout HEK293 Cell Line | EDJ-KQ12323 | Human | 441282 | Details Get a Quote |
| AKR1C3 Knockout A-549 Cell Line | EDJ-KQ21929 | Human | 8644 | Details Get a Quote |
| AKR1C3 Knockout HCT 116 Cell Line | EDJ-KQ21930 | Human | 8644 | Details Get a Quote |
| AKR1C3 Knockout HeLa Cell Line | EDJ-KQ21931 | Human | 8644 | Details Get a Quote |
Displaying Records 1 To 15 Of 49 Records
- 1
- 2
- Next Page »
Frequently Asked Questions About aldose reductase [NAD(P)H] activity
What is aldose reductase [NAD(P)H] activity?
It is a molecular function (GO:0004032) that catalyzes the NAD(P)H-dependent reduction of an aldose to an alditol, such as glucose to sorbitol.
What genes are involved in aldose reductase [NAD(P)H] activity?
Key genes include AKR1B1, AKR1A1, AKR1B10, and homologs in yeast and bacteria such as Candida tenuis AR and Pseudomonas aeruginosa crc [2,4,8].
What is the polyol pathway?
The polyol pathway is a two-step metabolic route that converts glucose to fructose via sorbitol, with aldose reductase [NAD(P)H] activity catalyzing the first step.
How is aldose reductase activity measured?
It is typically measured by spectrophotometric assays monitoring NAD(P)H oxidation at 340 nm using aldose substrates.
What diseases are linked to aldose reductase [NAD(P)H] activity?
Diabetic complications such as retinopathy and nephropathy, as well as non-small cell lung cancer, are linked to this activity [3,5].
Can CRISPR be used to study aldose reductase [NAD(P)H] activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional studies of this activity.
What is the role of NADPH in aldose reductase activity?
NADPH serves as the electron donor for the reduction of aldoses to alditols, and its availability regulates flux through the pathway [2,3].
Is aldose reductase [NAD(P)H] activity found in bacteria?
Yes, NAD(P)H-dependent carbonyl reductases with this activity have been characterized in Pseudomonas aeruginosa and other bacteria.
What are the synonyms for GO:0004032?
Synonyms include aldehyde reductase activity, alditol:NAD(P)+ 1-oxidoreductase activity, aldose reductase activity, and polyol dehydrogenase (NADP(+)) activity.
How does aldose reductase contribute to cancer?
In non-small cell lung cancer, polyol pathway-generated fructose is indispensable for growth and survival, and aldose reductase activity drives fructose production.
Conclusion
GO:0004032, aldose reductase [NAD(P)H] activity, is a fundamental oxidoreductase function that bridges glucose metabolism, redox balance, and biosynthetic precursor supply. Its role in the polyol pathway makes it a key player in diabetic complications and cancer metabolism, while its broad substrate specificity hints at additional physiological roles in steroid and xenobiotic metabolism [3,5,8]. Continued research using CRISPR-engineered models and advanced metabolomics will further clarify how this activity can be targeted therapeutically.
References
- 2. Neuhauser W et al.. 1997. NAD(P)H-dependent aldose reductase from the xylose-assimilating yeast Candida tenuis. Isolation, characterization and biochemical properties of the enzyme.. Biochem J 326 ( Pt 3)(Pt 3):683-92 PMID: 9307017
- 3. Schwab A et al.. 2025. Polyol pathway-generated fructose is indispensable for growth and survival of non-small cell lung cancer.. Cell Death Differ 32(4):587-597 PMID: 39567724
- 4. Li S et al.. 2017. Structure and characterization of a NAD(P)H-dependent carbonyl reductase from Pseudomonas aeruginosa PAO1.. FEBS Lett 591(12):1785-1797 PMID: 28524228
- 5. Frank RN. 1986. Aldose reductase activity and basement membrane thickening.. Metabolism 35(4 Suppl 1):35-40 PMID: 3083207
- 6. Covarrubias VG et al.. 2006. Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites.. Toxicol Lett 164(3):249-58 PMID: 16478651
- 7. Fukuda Y et al.. 2015. A novel NAD(P)H-dependent carbonyl reductase specifically expressed in the thyroidectomized chicken fatty liver: catalytic properties and crystal structure.. FEBS J 282(20):3918-28 PMID: 26206323
- 8. Wermuth B et al.. 1983. Aldose and aldehyde reductase exhibit isocorticosteroid reductase activity.. Eur J Biochem 131(2):423-6 PMID: 6403351
